文献速递肝病

基因验证靶点治疗NASH的治疗机会

Therapeutic opportunities for the treatment of NASH with genetically validated targets.
PubMed 文献 · J Hepatol · 2023-05-17

本文为迷你综述,回顾自2008年全基因组关联研究以来发现的与脂肪性肝病(FLD)相关的遗传变异,包括PNPLA3和HSD17B13等,并探讨基于这些遗传验证靶点的治疗机会,重点介绍目前正在临床试验中评估的靶向PNPLA3和HSD17B13的寡核苷酸疗法用于治疗非酒精性脂肪性肝炎(NASH)。

要点

  • PNPLA3等基因变异与肝脏脂肪含量改变相关,为FLD治疗提供潜在靶点。
  • 靶向PNPLA3和HSD17B13的寡核苷酸疗法正在临床试验中评估用于NASH治疗。
  • 遗传验证靶点为理解FLD代谢通路和开发疗法提供了依据。

核心结论

  • 遗传验证靶点(如PNPLA3和HSD17B13)为NASH治疗提供了治疗机会,靶向这些靶点的寡核苷酸疗法正在临床试验中评估。

研究设计与样本

  • 本文为迷你综述,回顾了从2008年开始的全基因组关联研究发现的与脂肪性肝病相关的遗传变异,并探讨基于遗传验证靶点的治疗机会。

主要发现

  • 2008年发现PNPLA3基因的单核苷酸多态性与肝脏脂肪含量改变相关。
  • 此后发现了多个与脂肪性肝病保护或风险增加相关的遗传变异。
  • 这些变异的识别揭示了导致脂肪性肝病的代谢通路,并使得潜在治疗靶点的识别成为可能。

关键数值与推荐

  • 靶向PNPLA3和HSD17B13的寡核苷酸疗法目前正在临床试验中评估用于治疗NASH。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The identification of genetic variants associated with fatty liver disease (FLD) from genome-wide association studies started in 2008 when single nucleotide polymorphisms in PNPLA3, the gene encoding patatin-like phospholipase domain-containing 3, were found to be associated with altered hepatic fat content. Since then, several genetic variants associated with protection from, or an increased risk of, FLD have been identified. The identification of these variants has provided insight into the metabolic pathways that cause FLD and enabled the identification of potential therapeutic targets. In this mini-review, we will examine the therapeutic opportunities derived from genetically validated targets in FLD, including oligonucleotide-based therapies targeting PNPLA3 and HSD17B13 that are currently being evaluated in clinical trials for the treatment of NASH (non-alcoholic steatohepatitis).

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Lindén D, Romeo S. Therapeutic opportunities for the treatment of NASH with genetically validated targets. J Hepatol. 2023. PMID: 37207913. doi:10.1016/j.jhep.2023.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。